MAP2K1 and familial pancreatic carcinoma: This is the first report of the use of second-generation MEK 1 and 2 inhibitor in combination with a chemotherapy agent that has generated a limited increased survival in a small subset of patients with pancreatic cancer with a known KRAS mutation.